Compare GCT & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCT | SVRA |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2022 | N/A |
| Metric | GCT | SVRA |
|---|---|---|
| Price | $37.71 | $6.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $24.00 | $6.88 |
| AVG Volume (30 Days) | 631.9K | ★ 3.1M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.32 | N/A |
| EPS | ★ 3.31 | N/A |
| Revenue | ★ $1,222,932,000.00 | N/A |
| Revenue This Year | $9.56 | N/A |
| Revenue Next Year | $7.08 | N/A |
| P/E Ratio | $11.60 | ★ N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $11.17 | $1.89 |
| 52 Week High | $40.75 | $6.98 |
| Indicator | GCT | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 61.83 | 79.38 |
| Support Level | $38.27 | $5.55 |
| Resistance Level | $40.75 | $6.98 |
| Average True Range (ATR) | 1.70 | 0.45 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 71.29 | 89.12 |
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia, with resellers in the U.S., Asia, and Europe, to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.